KalVista Pharma Q3 EPS $(0.84) Misses $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharma (NASDAQ:KALV) reported a Q3 EPS loss of $(0.84), missing the consensus estimate of $(0.77) by 9.09%. This represents a 12% increase in losses compared to the same period last year.
March 11, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
KalVista Pharma reported a larger than expected Q3 loss of $(0.84) per share, missing the $(0.77) estimate and showing a 12% increase in losses from the previous year.
The reported earnings miss and the increase in losses year-over-year are likely to negatively impact investor sentiment and could lead to a short-term decrease in KALV's stock price. The significance of the miss and the comparison to last year's performance are critical factors for investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100